<?xml version='1.0' encoding='utf-8'?>
<document id="23916407"><sentence text="A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human."><entity charOffset="145-154" id="DDI-PubMed.23916407.s1.e0" text="verapamil" /></sentence><sentence text="Verapamil and its major metabolite norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic"><entity charOffset="0-9" id="DDI-PubMed.23916407.s2.e0" text="Verapamil" /></sentence><sentence text=" Metabolic clearances of verapamil and norverapmil as well as their effects on CYP3A activity were firstly measured in pooled human liver microsomes"><entity charOffset="25-34" id="DDI-PubMed.23916407.s3.e0" text="verapamil" /><entity charOffset="39-50" id="DDI-PubMed.23916407.s3.e1" text="norverapmil" /><pair ddi="false" e1="DDI-PubMed.23916407.s3.e0" e2="DDI-PubMed.23916407.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23916407.s3.e0" e2="DDI-PubMed.23916407.s3.e1" /></sentence><sentence text=" The results showed that S-isomers were more preferential to be metabolized than R-isomers for both verapamil and norverapamil, and their inhibitory effects on CYP3A activity were also stereoselective with S-isomers more potent than R-isomers"><entity charOffset="114-126" id="DDI-PubMed.23916407.s4.e0" text="norverapamil" /></sentence><sentence text=" A semi-physiologically based pharmacokinetic model (semi-PBPK) characterizing mechanism-based auto-inhibition was developed to predict the stereoselective pharmacokinetic profiles of verapamil and norverapamil following single or multiple oral doses"><entity charOffset="184-193" id="DDI-PubMed.23916407.s5.e0" text="verapamil" /><entity charOffset="198-210" id="DDI-PubMed.23916407.s5.e1" text="norverapamil" /><pair ddi="false" e1="DDI-PubMed.23916407.s5.e0" e2="DDI-PubMed.23916407.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23916407.s5.e0" e2="DDI-PubMed.23916407.s5.e1" /></sentence><sentence text=" Good simulation was obtained, which indicated that the developed semi-PBPK model can simultaneously predict pharmacokinetic profiles of S-verapamil, R-verapamil, S-norverapamil and R-norverapamil"><entity charOffset="137-148" id="DDI-PubMed.23916407.s6.e0" text="S-verapamil" /><entity charOffset="150-161" id="DDI-PubMed.23916407.s6.e1" text="R-verapamil" /><entity charOffset="163-177" id="DDI-PubMed.23916407.s6.e2" text="S-norverapamil" /><entity charOffset="182-196" id="DDI-PubMed.23916407.s6.e3" text="R-norverapamil" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e0" e2="DDI-PubMed.23916407.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e0" e2="DDI-PubMed.23916407.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e0" e2="DDI-PubMed.23916407.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e0" e2="DDI-PubMed.23916407.s6.e3" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e1" e2="DDI-PubMed.23916407.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e1" e2="DDI-PubMed.23916407.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e1" e2="DDI-PubMed.23916407.s6.e3" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e2" e2="DDI-PubMed.23916407.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23916407.s6.e2" e2="DDI-PubMed.23916407.s6.e3" /></sentence><sentence text=" Contributions of auto-inhibition to verapamil and norverapamil accumulation were also investigated following the 38th oral dose of verapamil sustained-release tablet (240mg once daily)"><entity charOffset="132-141" id="DDI-PubMed.23916407.s7.e0" text="verapamil" /></sentence><sentence text=" The predicted accumulation ratio was about 1" /><sentence text="3-1" /><sentence text="5 fold, which was close to the observed data of 1" /><sentence text="4-2" /><sentence text="1-fold" /><sentence text=" Finally, the developed semi-PBPK model was further applied to predict drug-drug interactions (DDI) between verapamil and other three CYP3A substrates including midazolam, simvastatin, and cyclosporine A"><entity charOffset="161-170" id="DDI-PubMed.23916407.s13.e0" text="midazolam" /><entity charOffset="172-183" id="DDI-PubMed.23916407.s13.e1" text="simvastatin" /><entity charOffset="189-203" id="DDI-PubMed.23916407.s13.e2" text="cyclosporine A" /><pair ddi="false" e1="DDI-PubMed.23916407.s13.e0" e2="DDI-PubMed.23916407.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23916407.s13.e0" e2="DDI-PubMed.23916407.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23916407.s13.e0" e2="DDI-PubMed.23916407.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23916407.s13.e1" e2="DDI-PubMed.23916407.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23916407.s13.e1" e2="DDI-PubMed.23916407.s13.e2" /></sentence><sentence text=" Successful prediction was also obtained, which indicated that the developed semi-PBPK model incorporating auto-inhibition also showed great advantage on DDI prediction with CYP3A substrates" /><sentence text=" " /></document>